B cell receptor inhibition as a target for CLL therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Baillière's Best Practice & Research: Clinical Haematology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.beha.2016.08.004PMID 27742069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted therapies in CLL: mechanisms of resistance and strategies for management.

  2015cited by this paper
• Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor

  2015cited by this paper
• Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.

  2015cited by this paper
• Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.

  2015cited by this paper
• Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

  2015cited by this paper
• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

  2015cited by this paper
• Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

  2015cited by this paper
• The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

  2015cited by this paper
• Secondary mutations as mediators of resistance to targeted therapy in leukemia.

  2015cited by this paper
• Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

  2015cited by this paper
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

  2015cited by this paper
• Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL.

  2015cited by this paper
• Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

  2015cited by this paper
• Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

  2015cited by this paper
• Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014influential reference
• Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

  2014cited by this paper
• TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

  2014cited by this paper
• Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

  2014cited by this paper
• IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

  2014cited by this paper
• Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial

  2014cited by this paper
• Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

  2014cited by this paper
• Activity of TGR-1202, a novel once-daily PI3K{delta} inhibitor, in patients with relapsed or refractory hematologic malignancies.

  2014cited by this paper
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

  2014cited by this paper
• Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

  2014cited by this paper
• BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

  2014cited by this paper
• Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition

  2013cited by this paper
• Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

  2013cited by this paper
• First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies

  2013cited by this paper
• Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

  2013cited by this paper
• A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

  2013cited by this paper
• Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.

  2012cited by this paper
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• Targeted covalent drugs of the kinase family.

  2010cited by this paper
• Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

  2009cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Perspectives on the nature of BCR-mediated survival signals.

  2004cited by this paper
• B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease

  2002cited by this paper

• Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape

  2020cites this paper
• SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2

  2020cites this paper
• Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors

  2019cites this paper
• Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

  2019cites this paper
• Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia

  2019cites this paper
• Ibrutinibrezisztencia krónikus limfocitás leukémiában

  2019cites this paper
• Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL

  2018cites this paper
• Idelalisib.

  2018cites this paper
• Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

  2017cites this paper
• Infectious and bleeding complications in patients with hematological malignancies : Studies on diagnosis and prevention

  2017cites this paper